Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review

Jetske van der Schaar*, Leonie N.C. Visser, Femke H. Bouwman, Johannes C.F. Ket, Philip Scheltens, Annelien L. Bredenoord, Wiesje M. van der Flier

*Corresponding author for this work

Research output: Contribution to journalReview articlePopular

28 Citations (Scopus)
105 Downloads (Pure)

Abstract

BACKGROUND: The NIA-AA research framework proposes a purely biological definition of Alzheimer's disease (AD). This implies that AD can be diagnosed based on biomarker abnormalities, irrespective of clinical manifestation. While this brings opportunities, it also raises challenges. We aimed to provide an overview of considerations regarding the disclosure of AD pathology before the onset of dementia. METHODS: A systematic literature review was conducted and reported according to PRISMA guidelines. We searched PubMed, Embase, APA PsycINFO, and Web of Science Core Collection (on 10 December 2020) for references on conveying AD biomarker results to individuals without dementia. Our query combined variations on the terms Alzheimer's disease, disclosure, or diagnosis, preclinical or prodromal, and biomarkers. Two reviewers independently screened the resulting 6860 titles and abstracts for eligibility and examined 162 full-text records for relevance. We included theoretical articles in English, on communicating amyloid and/or tau results to individuals with mild cognitive impairment, subjective cognitive decline, or normal cognition. MAXQDA-software was used for inductive data analysis. RESULTS: We included 27 publications. From these, we extracted 26 unique considerations, which we grouped according to their primary relevance to a clinical, personal, or societal context. Clinical considerations included (lack of) validity, utility, and disclosure protocols. Personal considerations covered psychological and behavioral implications, as well as the right to (not) know. Finally, societal considerations comprised the risk of misconception, stigmatization, and discrimination. Overall, views were heterogeneous and often contradictory, with emphasis on harmful effects. CONCLUSIONS: We found 26 diverse and opposing considerations, related to a clinical, personal, or societal context, which are relevant to diagnosing AD before dementia. The theoretical literature tended to focus on adverse impact and rely on common morality, while the motivation for and implications of biomarker testing are deeply personal. Our findings provide a starting point for clinicians to discuss biomarker-based diagnosis with their patients, which will become even more relevant in light of the conditional approval of a first disease-modifying drug for AD.

Original languageEnglish
Article number31
JournalAlzheimer's research & therapy
Volume14
Issue number1
DOIs
Publication statusPublished - Dec 2022

Bibliographical note

Funding:
JvdS is appointed at ABOARD, which is a public-private partnership receiving
funding from ZonMW (#73305095007) and Health~Holland, Topsector Life
Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners
participate in ABOARD

Publisher Copyright: © 2022. The Author(s).

Fingerprint

Dive into the research topics of 'Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review'. Together they form a unique fingerprint.

Cite this